Cardiovascular Diabetology · 2008 · 14 citations · 55 references
Life SciencesBiochemistryPharmacologyCardiovascular PharmacotherapyInflammationMetabolic RegulationAtherosclerosis PharmacotherapyCardiovascular DiseaseGene Expression Responses To DietLipid MetabolismLipid-lowering TherapyLipoprotein MetabolismAnti-inflammatory ResponseAntioxidant PharmacologyAntioxidant PropertiesAntioxidant TreatmentAtherosclerosis Molecular MechanismsAtherosclerotic Cardiovascular Risk ReductionAtherosclerotic Lipid AccumulationCholesterol-lowering Diets
BACKGROUND: Thiazolidinediones exert anti-inflammatory and anti-oxidative roles and attenuate atherosclerosis by mechanisms partially independent of their metabolizing actions. High doses of angiotensin type 1 receptor (AT1R) blocker losartan (LST) seem to promote fat cell formation by preserving PPARgamma activity. METHODS: C57BL/6J diet-induced atherosclerotic susceptible mice randomly received a normal or a high-fat high-cholesterol (HFHC) diet and were treated with rosiglitazone (RG), LST or a vehicle for 12 weeks. RESULTS: HFHC was associated with increased PPARgamma gene expression without an over regulation of PPARgamma responsive genes, whereas RG and LST treatments were found to maintain PPARgamma activity without resulting in increased PPARgamma gene expression. A better anti-inflammatory and antioxidant profile in mice treated with RG regarding LST was observed in spite of a similar PPARgamma preserved activity. Chromatin immunoprecipitation (ChIP) assays revealed that animals under HFHC diet treated with RG showed a significant nuclear factor erythroid 2-like 2 (Nrf2)-dependent down-regulation of the expression of the CD36 gene. CONCLUSION: The PPARgamma agonist RG exerts antioxidant properties that significantly reduced Nrf-2-dependent CD-36 up-regulation in mice under HFHC diet. Because LST treatment was also associated with a preserved PPARgamma activity, our data suggests that these RG antioxidant effects are partially independent of its PPARgamma metabolizing properties.
55
Primer3 on the WWW for General Users and for Biologist Programmers
Steve Rozen, Helen Skaletsky · Humana Press eBooks · 2003 · 15.1K citations
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Mercedes Ricote, Andrew C. Li, Timothy M. Willson et al. · Nature · 1998 · 3.5K citations
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Chengyu Jiang, Adrian T. Ting, Brian Seed · Nature · 1998 · 2.9K citations
Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ
László Nagy, Peter Tontonoz, Jacqueline G. Alvarez et al. · Cell · 1998 · 1.9K citations · Full text